These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 28328346)

  • 1. Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger.
    Isanaka S; Guindo O; Langendorf C; Matar Seck A; Plikaytis BD; Sayinzoga-Makombe N; McNeal MM; Meyer N; Adehossi E; Djibo A; Jochum B; Grais RF
    N Engl J Med; 2017 Mar; 376(12):1121-1130. PubMed ID: 28328346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of human rotavirus vaccine on severe diarrhea in African infants.
    Madhi SA; Cunliffe NA; Steele D; Witte D; Kirsten M; Louw C; Ngwira B; Victor JC; Gillard PH; Cheuvart BB; Han HH; Neuzil KM
    N Engl J Med; 2010 Jan; 362(4):289-98. PubMed ID: 20107214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.
    Armah GE; Sow SO; Breiman RF; Dallas MJ; Tapia MD; Feikin DR; Binka FN; Steele AD; Laserson KF; Ansah NA; Levine MM; Lewis K; Coia ML; Attah-Poku M; Ojwando J; Rivers SB; Victor JC; Nyambane G; Hodgson A; Schödel F; Ciarlet M; Neuzil KM
    Lancet; 2010 Aug; 376(9741):606-14. PubMed ID: 20692030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial.
    Isanaka S; Langendorf C; McNeal MM; Meyer N; Plikaytis B; Garba S; Sayinzoga-Makombe N; Soumana I; Guindo O; Makarimi R; Scherrer MF; Adehossi E; Ciglenecki I; Grais RF
    PLoS Med; 2021 Jul; 18(7):e1003655. PubMed ID: 34214095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.
    Zaman K; Dang DA; Victor JC; Shin S; Yunus M; Dallas MJ; Podder G; Vu DT; Le TP; Luby SP; Le HT; Coia ML; Lewis K; Rivers SB; Sack DA; Schödel F; Steele AD; Neuzil KM; Ciarlet M
    Lancet; 2010 Aug; 376(9741):615-23. PubMed ID: 20692031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life.
    Bhandari N; Rongsen-Chandola T; Bavdekar A; John J; Antony K; Taneja S; Goyal N; Kawade A; Kang G; Rathore SS; Juvekar S; Muliyil J; Arya A; Shaikh H; Abraham V; Vrati S; Proschan M; Kohberger R; Thiry G; Glass R; Greenberg HB; Curlin G; Mohan K; Harshavardhan GV; Prasad S; Rao TS; Boslego J; Bhan MK;
    Vaccine; 2014 Aug; 32 Suppl 1():A110-6. PubMed ID: 25091663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants.
    Kulkarni PS; Desai S; Tewari T; Kawade A; Goyal N; Garg BS; Kumar D; Kanungo S; Kamat V; Kang G; Bavdekar A; Babji S; Juvekar S; Manna B; Dutta S; Angurana R; Dewan D; Dharmadhikari A; Zade JK; Dhere RM; Fix A; Power M; Uprety V; Parulekar V; Cho I; Chandola TR; Kedia VK; Raut A; Flores J;
    Vaccine; 2017 Oct; 35(45):6228-6237. PubMed ID: 28967523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of the oral pentavalent rotavirus vaccine in Mali.
    Sow SO; Tapia M; Haidara FC; Ciarlet M; Diallo F; Kodio M; Doumbia M; Dembélé RD; Traoré O; Onwuchekwa UU; Lewis KD; Victor JC; Steele AD; Neuzil KM; Kotloff KL; Levine MM
    Vaccine; 2012 Apr; 30 Suppl 1():A71-8. PubMed ID: 22520140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth.
    Bines JE; At Thobari J; Satria CD; Handley A; Watts E; Cowley D; Nirwati H; Ackland J; Standish J; Justice F; Byars G; Lee KJ; Barnes GL; Bachtiar NS; Viska Icanervilia A; Boniface K; Bogdanovic-Sakran N; Pavlic D; Bishop RF; Kirkwood CD; Buttery JP; Soenarto Y
    N Engl J Med; 2018 Feb; 378(8):719-730. PubMed ID: 29466164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial.
    Bhandari N; Rongsen-Chandola T; Bavdekar A; John J; Antony K; Taneja S; Goyal N; Kawade A; Kang G; Rathore SS; Juvekar S; Muliyil J; Arya A; Shaikh H; Abraham V; Vrati S; Proschan M; Kohberger R; Thiry G; Glass R; Greenberg HB; Curlin G; Mohan K; Harshavardhan GV; Prasad S; Rao TS; Boslego J; Bhan MK;
    Lancet; 2014 Jun; 383(9935):2136-43. PubMed ID: 24629994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of a heat-stable rotavirus vaccine among children in Niger: Data from a phase 3, randomized, double-blind, placebo-controlled trial.
    Coldiron ME; Guindo O; Makarimi R; Soumana I; Matar Seck A; Garba S; Macher E; Isanaka S; Grais RF
    Vaccine; 2018 Jun; 36(25):3674-3680. PubMed ID: 29752026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.
    Ruiz-Palacios GM; Pérez-Schael I; Velázquez FR; Abate H; Breuer T; Clemens SC; Cheuvart B; Espinoza F; Gillard P; Innis BL; Cervantes Y; Linhares AC; López P; Macías-Parra M; Ortega-Barría E; Richardson V; Rivera-Medina DM; Rivera L; Salinas B; Pavía-Ruz N; Salmerón J; Rüttimann R; Tinoco JC; Rubio P; Nuñez E; Guerrero ML; Yarzábal JP; Damaso S; Tornieporth N; Sáez-Llorens X; Vergara RF; Vesikari T; Bouckenooghe A; Clemens R; De Vos B; O'Ryan M;
    N Engl J Med; 2006 Jan; 354(1):11-22. PubMed ID: 16394298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.
    Breiman RF; Zaman K; Armah G; Sow SO; Anh DD; Victor JC; Hille D; Ciarlet M; Neuzil KM
    Vaccine; 2012 Apr; 30 Suppl 1():A24-9. PubMed ID: 22520132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.
    Feikin DR; Laserson KF; Ojwando J; Nyambane G; Ssempijja V; Audi A; Nyakundi D; Oyieko J; Dallas MJ; Ciarlet M; Neuzil KM; Breiman RF
    Vaccine; 2012 Apr; 30 Suppl 1():A52-60. PubMed ID: 22520137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
    Vesikari T; Matson DO; Dennehy P; Van Damme P; Santosham M; Rodriguez Z; Dallas MJ; Heyse JF; Goveia MG; Black SB; Shinefield HR; Christie CD; Ylitalo S; Itzler RF; Coia ML; Onorato MT; Adeyi BA; Marshall GS; Gothefors L; Campens D; Karvonen A; Watt JP; O'Brien KL; DiNubile MJ; Clark HF; Boslego JW; Offit PA; Heaton PM;
    N Engl J Med; 2006 Jan; 354(1):23-33. PubMed ID: 16394299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
    Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
    Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study.
    Linhares AC; Velázquez FR; Pérez-Schael I; Sáez-Llorens X; Abate H; Espinoza F; López P; Macías-Parra M; Ortega-Barría E; Rivera-Medina DM; Rivera L; Pavía-Ruz N; Nuñez E; Damaso S; Ruiz-Palacios GM; De Vos B; O'Ryan M; Gillard P; Bouckenooghe A;
    Lancet; 2008 Apr; 371(9619):1181-9. PubMed ID: 18395579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study.
    Vesikari T; Karvonen A; Prymula R; Schuster V; Tejedor JC; Cohen R; Meurice F; Han HH; Damaso S; Bouckenooghe A
    Lancet; 2007 Nov; 370(9601):1757-63. PubMed ID: 18037080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.
    Goveia MG; Rodriguez ZM; Dallas MJ; Itzler RF; Boslego JW; Heaton PM; DiNubile MJ;
    Pediatr Infect Dis J; 2007 Dec; 26(12):1099-104. PubMed ID: 18043445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial.
    Madhi SA; Kirsten M; Louw C; Bos P; Aspinall S; Bouckenooghe A; Neuzil KM; Steele AD
    Vaccine; 2012 Apr; 30 Suppl 1():A44-51. PubMed ID: 22520136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.